ArticleBiotechnology for biofuels and bioproducts2024
Engineering cyanobacteria as a new platform for producing taxol precursors directly from carbon dioxide.
Article in Biotechnology for biofuels and bioproducts, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Enhancing Geranylgeranyl Pyrophosphate Supply in Engineered Cyanobacteria for Improved Production of Natural Pigments and Terpenoid Precursors.International journal of molecular sciences · 2026Article
- Cyanobacteria as a Photosynthetic Chassis for Metabolic Pathway Engineering with Heterologous Gene Expression.Current issues in molecular biology · 2026Review
- Investigating synergistic effects of key medium components and pectin elicitor on taxane fermentation in Neopestalotiopsis vitis: A Box-Behnken response surface methodology approach.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Toward Sustainable Paclitaxel Bioproduction: Plant Biology, Biosynthesis and Platform Engineering.Plants (Basel, Switzerland) · 2026Review
- Regulating protein glycosylation modification enhances the synthesis of taxadiene inSynthetic and systems biotechnology · 2026Article
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
- The biosynthesis and diversity of taxanes: From pathway elucidation to engineering and synthetic biology.Plant communications · 2025Review
- Plant synthetic biology-based biofortification, strategies and recent progresses.Journal of integrative plant biology · 2025Review
- The Sustainable Production of Terpenoids in Cyanobacterial Chassis.Microorganisms · 2025Review
- Development of a CRISPR activation system for targeted gene upregulation in Synechocystis sp. PCC 6803.Communications biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Taxol serves as an efficient natural anticancer agent with extensive applications in the treatment of diverse malignancies. Although advances in synthetic biology have enabled the de novo synthesis of taxol precursors in various microbial chassis, the total biosynthesis of taxol remains challengable owing to the restricted oxidation efficiency in heterotrophic microbes. Here, we engineered Synechocystis sp. PCC 6803 with modular metabolic pathways consisting of the methylerythritol phosphate pathway enzymes and taxol biosynthetic enzymes for production of taxadiene-5α-ol (T5α-ol), the key oxygenated intermediate of taxol. The best strain DIGT-P560 produced up to 17.43 mg/L of oxygenated taxanes and 4.32 mg/L of T5α-ol. Moreover, transcriptomic analysis of DIGT-P560 revealed that establishing a oxygenated taxane flux may enhance photosynthetic electron transfer efficiency and central metabolism in the engineered strain to ameliorate the metabolic disturbances triggered by the incorporation of exogenous genes. This is the first demonstration of photosynthetic production of taxadiene-5α-ol from CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.